Evidence map›Paper›PMID 35116745›Full record

ArticleTranslational cancer research2019

Characterization of microRNA expression profiles by deep sequencing of small RNA libraries in leukemia patients from Naxi ethnic.

Zhenglei Shen, Xuezhong Gu, Wenwen Mao, Honghua Cao, Rui Zhang, Yeying Zhou, Kunmei Liu, Lilan Wang, Zhe Zhang, Liefen Yin

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. MiRNA-339 targets and regulatesTranslational cancer research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zhenglei Shen *Department of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
Xuezhong Gu *Department of Hematology, The First People's Hospital of Yunnan Province, Kunming 650000, China.
Wenwen MaoDepartment of Geriatics, The Second Hospital of Kunming, Kunming 650000, China.
Honghua CaoDepartment of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
Rui ZhangDepartment of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
Yeying ZhouDepartment of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
Kunmei LiuDepartment of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
Lilan WangDepartment of Hematology, The Third Affiliated Hospital of Kunming Medical University, Kunming 650000, China.
Zhe ZhangDepartment of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650031, China.
Liefen YinDepartment of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650031, China.
Kunming Medical University · CNFirst People's Hospital of Yunnan Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeukemia is a hematological malignancy characterized by the proliferation of early lymphoid precursors that replaces normal hematopoietic cells of the bone marrow. Nakhi (Naxi) ethnic minorities considered to be an area of low incidence. MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate the expression of other genes in various biological processes. The purpose of this work is to study the molecular mechanism of miRNAs in the leukemia from Naxi.

methodsSix leukemia patients (case 2 to case 7) and one healthy person (case 1) from Nakhi (Naxi) ethnic minorities were recruited. Total RNA was extracted from these samples and small RNA deep sequencing was performed.

resultsA list of miRNAs (1,392 known and candidate 125 novels) expressed in leukocytes were identified, and many differentially regulated targets involved in several cellular pathways, such as cancer, Rap1 signaling pathway, Ras signaling pathway, and endocytosis. Additionally, quantitative real time-polymerase chain reaction (qRT-PCR) results show that hsa-miR-181b-5p, hsa-miR-181a-3p, hsa-miR-181a-5p, and hsa-miR-342-3p has different expression patterns in different cancer cells, hsa-miR-450a-5p, and hsa-miR-1255a were dysregulated in all leukemia cells.

conclusionsSeveral abnormal expressed miRNAs in leukemia patients were identified, the correlation of miRNAs dysregulation and leukemia biology demonstrates that specific miRNA can be potential therapeutic target.

Indexed as

expression profileleukemialeukemia cellsMicroRNA (miRNA)NaxinovelpathwayRNA sequencing

Identifiers

PMID35116745
PMCPMC8798052
OpenAlexW4231759445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.